Catalyst Biosciences Announces Presentations on its Next-Generation Subcutaneous Hemophilia Product Candidates at the 2017 In...
June 08 2017 - 8:00AM
-- Factor IX oral presentation & Factor VIIa
poster presentation --
Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications, today announced that data from two
of its product candidates will be presented at the International
Society on Thrombosis and Haemostasis (ISTH) Meeting being held in
Berlin, Germany from July 8 to 13, 2017.
Catalyst is focused on the prevention of bleeding in individuals
with hemophilia through the development of clotting factors that
may be injected subcutaneously, rather than intravenously,
potentially achieving normal coagulation activity.
Catalyst recently announced that CB 2679d/ISU304, its
next-generation Factor IX variant, received a positive Orphan Drug
Designation recommendation in the EU. Catalyst’s South Korean
collaborator, ISU Abxis, plans to initiate a Phase 1/2
proof-of-concept study of CB 2679d in individuals with severe
hemophilia B in June 2017 in South Korea.
The presentations being made by Catalyst are as follows:
Oral PresentationFactor
IX: CB 2679d/ISU304 is a next-generation coagulation
Factor IX variant that is IND-approved in South Korea.
Title |
Pharmacokinetic and
Activity Levels Achieved with Daily Subcutaneously Administered CB
2679d/ISU304 in Hemophilia B Dogs |
Presenter |
Howard Levy, M.B.B.Ch.,
Ph.D., M.M.M. |
Session |
Future Biotherapeutics
for Hemophilia A and B Monday, July 10, 2017 at 10:00 am CET |
Poster PresentationFactor
VIIa: Marzeptacog alfa (activated) is a
next-generation Factor VIIa that successfully completed an
intravenous Phase 1 clinical trial in severe hemophilia A and B
with and without inhibitors. Catalyst plans to initiate a
subcutaneous dosing efficacy study of marzeptacog alfa (activated)
in individuals with hemophilia B with inhibitors in 2017.
Title: |
|
Pharmacokinetics and
Pharmacodynamics of Subcutaneously Administered |
|
Marzeptacog Alfa
(Activated) in Hemophilia B Mice, Levy et al. |
|
Tuesday, July 11, 2017
from 12:00-13:15 pm CET |
About Factor IXCB 2679d/ISU304 is a
next-generation coagulation Factor IX variant that is IND-approved
in South Korea. Catalyst believes that CB 2679d/ISU304 may
allow for subcutaneous prophylactic treatment of individuals with
hemophilia B. Learn more about Factor IX.
About Factor VIIaMarzeptacog alfa (activated)
is a high potency next-generation Factor VIIa that is initially
being developed for the subcutaneous prophylactic treatment of
severe hemophilia A and B patients with inhibitors. Learn more
about Factor VIIa.
About Hemophilia and Factor Replacement Therapy
Hemophilia, for which there is no cure, is a rare but serious
bleeding disorder that results from a genetic or an acquired
deficiency of a protein required for normal blood coagulation.
Individuals with hemophilia suffer from spontaneous bleeding
episodes as well as substantially prolonged bleeding times upon
injury. Learn more about hemophilia.
About Catalyst Catalyst is a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications. Catalyst is focused on the field of
hemostasis, including the subcutaneous prophylaxis of hemophilia
and facilitating surgery in individuals with hemophilia. For more
information, visit www.catalystbiosciences.com.
Forward-Looking Statements This press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statement of
historical facts, included in this press release regarding our
strategy, future operations, and plans are forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Catalyst’s clinical trial
timelines, including the initiation of an efficacy study for
marzeptacog alfa (activated) in 2017 and of a Phase 1/2 clinical
trial for Factor IX CB 2679d/ISU304 in June 2017, and the potential
uses and benefits of subcutaneously dosed marzeptacog alfa
(activated) and CB 2679d/ISU304. Actual results or events could
differ materially from the plans, intentions, expectations and
projections disclosed in the forward-looking statements. Various
important factors could cause actual results or events to differ
materially from the forward-looking statements that Catalyst makes,
including, but not limited to, the risk that trials and studies may
be delayed and may not have satisfactory outcomes, that human
trials will not replicate the results from animal studies, that
potential adverse effects may arise from the testing or use of
Catalyst’s products, including the generation of antibodies, the
risk that costs required to develop or manufacture Catalyst’s
products will be higher than anticipated, competition and other
factors that affect our ability to successfully develop,
manufacture and commercialize our product candidates described in
the “Risk Factors” section of the Company’s Annual Report on Form
10-K and Quarterly Reports on Form 10-Q filed with the SEC.
Catalyst does not assume any obligation to update any
forward-looking statements, except as required by law.
Contacts:
Investors:
Fletcher Payne, CFO
Catalyst Biosciences, Inc.
650.871.0761
investors@catbio.com
Media:
Denise Powell
Red House Consulting, LLC
510.703.9491
denise@redhousecomms.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024